EGFR and non-small cell lung carcinoma: Accordingly, preclinical data have indicated that EGFR-mutants can induce NSCLC development in part through upregulation and activation of β-catenin and that CTNNB1-mutations represent a potential downstream mechanism of acquired resistance to EGFR-TKIs [177,178,179].